First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab plus Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck

被引：2
|
作者：
Remenar, E. [1 ]
Loevey, J. [2 ]
Koltai, P. [1 ]
Horvath, K. [2 ]
Goedeny, M. [2 ]
Kasler, M. [1 ]
机构：
[1] Natl Inst Oncol Head & Neck Oncol, Budapest, Hungary
[2] Natl Inst Oncol, Budapest, Hungary
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)72175-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [21] INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT RADIOTHERAPY PLUS CETUXIMAB IN PATIENTS WITH UNRESECTABLE ADVANCED HEAD AND NECK CANCER
    Calvo, M.
    Vazquez, S.
    Lozano, A.
    Teule, A.
    Manos, M.
    Nogues, J.
    Perez, X.
    Vilajosana, E.
    Elez, E.
    Mesia, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 221 - 221
  • [22] Induction chemotherapy with docetaxel, cisplatin, 5 FU, followed by radiotherapy plus cisplatin or cetuximab, in organ preservation in piriform sinus carcinomas.
    Fayette, Jerome
    Fuchsmann, Carine
    Tartas, Sophie
    Favrel, Veronique
    Pommier, Pascal
    Zrounba, Philippe
    Ramade, Antoine
    Racadot, Severine
    Ceruse, Philippe
    Poupart, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Compliance and efficacy of induction chemotherapy with cisplatin, docetaxel, and fluorouracil followed by radiotherapy plus cisplatin or cetuximab for locally advanced oropharyngeal tumours.
    Fuchsmann, Carine
    Fayette, Jerome
    Tartas, Sophie
    Favrel, Veronique
    Pommier, Pascal
    Zrounba, Philippe
    Ramade, Antoine
    Racadot, Severine
    Poupart, Marc
    Ceruse, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Goshi Nishimura
    Takahide Taguchi
    Masahiro Takahashi
    Osamu Shiono
    Masanori Komatsu
    Daisuke Sano
    Kenichiro Yabuki
    Yasuhiro Arai
    Hideaki Takahashi
    Masaharu Hata
    Nobuhiko Oridate
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1315 - 1319
  • [25] Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma
    Nishimura, Goshi
    Taguchi, Takahide
    Takahashi, Masahiro
    Shiono, Osamu
    Komatsu, Masanori
    Sano, Daisuke
    Yabuki, Kenichiro
    Arai, Yasuhiro
    Takahashi, Hideaki
    Hata, Masaharu
    Oridate, Nobuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (06) : 1315 - 1319
  • [26] Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer
    Ahn, P.
    Machtay, M.
    Anne, P. R.
    Wuthrick, E.
    Keane, W. M.
    Keane, W. M.
    Cognetti, D.
    Dicker, A. P.
    Axelrod, R. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S437 - S437
  • [27] Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
    Griffin, S.
    Walker, S.
    Sculpher, M.
    White, S.
    Erhorn, S.
    Brent, S.
    Dyker, A.
    Ferrie, L.
    Gilfillan, C.
    Horsley, W.
    Macfarlane, K.
    Thomas, S.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [28] Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer
    Hitt, Ricardo
    Mesia, Ricard
    Lozano, Alicia
    Iglesias Docampo, Lara
    Grau, Juan J.
    Taberna, Miren
    Rubio-Casadevall, Jordi
    Martinez-Trufero, Javier
    del Barco Morillo, Edel
    Garcia Giron, Carlos
    Vazquez Estevez, Sergio
    Cirauqui, Beatriz
    Jesus Cruz-Hernandez, Juan
    ORAL ONCOLOGY, 2022, 134
  • [29] HYPOMAGNESAEMIA AFTER INDUCTION TPF CHEMOTHERAPY FOLLOWED BY CONCOMITANT CISPLATIN/CETUXIMAB/RADIOTHERAPY (CCRT) IN LOCALLY ADVANCED HEAD AND NECK CANCER (LAHNC)
    Kuhar, C. Grasic
    Strojan, P.
    Zakotnik, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 320 - 321
  • [30] Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: the phase II ADVANTAGE trial
    Gauler, T. C.
    Clement, P. M.
    Peyrade, F.
    Krauss, J.
    Mesia, R.
    Remenar, E.
    Keilholz, U.
    Delord, J. P.
    Schafhausen, P.
    Erfan, J.
    Brummendorf, T. H.
    Iglesias, L.
    Bethe, U.
    Hicking, C.
    Vermorken, J. B.
    ONKOLOGIE, 2012, 35 : 193 - 194
12345